(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 22.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.4%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.44%.
Mirum Pharmaceuticals's revenue in 2026 is $521,312,000.On average, 12 Wall Street analysts forecast MIRM's revenue for 2026 to be $39,197,914,403, with the lowest MIRM revenue forecast at $34,239,040,318, and the highest MIRM revenue forecast at $41,392,539,013. On average, 11 Wall Street analysts forecast MIRM's revenue for 2027 to be $47,725,391,718, with the lowest MIRM revenue forecast at $41,987,507,357, and the highest MIRM revenue forecast at $53,335,351,850.
In 2028, MIRM is forecast to generate $58,465,596,127 in revenue, with the lowest revenue forecast at $52,083,263,297 and the highest revenue forecast at $68,186,027,210.